Log in with your email address username.


[Viewpoint] Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries

An estimated 80–150 million people are infected with hepatitis C virus (HCV) worldwide, with the highest prevalence in low-income and medium-income countries of Africa and Asia. HCV-related liver disease mortality is estimated to be half a million per annum.1,2